chinese/protease

In the absence of a validated treatment, any patient over 75 years -or demented above 60- of age arriving in one of our hospital centres with a COVID19 infection objectified by RT-PCR will be offered this therapeutic trial. Patients will be randomized. During their hospitalization, they will be

The study agent, VRC-HIVMAB060-00-antibody (AB), was manufactured for the VRC by the Vaccine Pilot Plant operated by Leidos Biomedical Research, Inc, formerly SAIC-Frederick, Inc, Frederick, MD. Specific manufacturing information is included on the product vial labels and Certificates of Analysis

This protocol has been prepared by the Systemic Autoimmune Diseases Group (GEAS) steering committee from the Spanish Society of Internal Medicine (SEMI) in response to the current urgent situation that are living in Spain because of the COVID-19 pandemic. The GEAS member are experts in the treatment

Objectives 1. To demonstrate the presence of NE in vitro and the entrance into lung adenocarcinoma cells 2. To identify the intracellular mechanisms through which NE mediates its tumor proliferating effects 3. To verify the activation of NE and its related pathway component in clinical lung

The study is a randomized interventional comparative Phase II trial. The duration of the trial for each subject is expected to be 3 months.160 adult male and female patients with positive COVID-19 diagnosis and fulfilling the below outlined inclusion criteria will be enrolled into the study. Trial

Study Rationale Over 100 patients were hospitalized at Hadassah in the recent 2 months with the diagnosis of COVID19. We would like to summarize the clinical outcomes and their correlation to a cytokine storm at Hadassah and additional hospitals and additional hospitals in Israel. COVID-19, the name

The study is a randomized interventional comparative Phase III trial. 1000 adult male and female patients with positive COVID-19 diagnosis and fulfilling the below outlined inclusion criteria will be enrolled into the study. Isotretinoin(13cis RA) may be able to inhibit COVID 2019 entry via down

Research Background and Rationale At the end of December 2019, pneumonia of unknown origin was detected in the hospitals of Wuhan city, China, and reported to the WHO country office for the first time [1-3]. After a few days, the Chinese government has confirmed the human-to-human transmission of